Sandbox Reserved 1068: Difference between revisions

Revision as of 06:56, 11 April 2015 view source Robin C. Gagnon (talk \| contribs) 87 edits No edit summary ← Older edit		Revision as of 06:58, 11 April 2015 view source Robin C. Gagnon (talk \| contribs) 87 edits No edit summary Newer edit →
Line 57:		Line 57:
	==Inhibition Studies==		==Inhibition Studies==

	MbtI Inhibition studies aid in the future design of anti-tubercular agents and broad-spectrum antibiotics. Mimics of the enzyme-bound intermediate of MbtI, isochorismate, prove to be significantly more potent inhibitors than the substrate, chorismate mimics <ref name= "manos-turvey"</~~ref~~>. Specifically, <scene name='69/694235/3rv6_with_vae1/1'>2-hydroxybenzoate-based inhibitors</scene> that contain extended hydrophobic enol ether side chains at C3 in place of the enol-pyruvate side chain found in chorismate and isochorismate.		MbtI Inhibition studies aid in the future design of anti-tubercular agents and broad-spectrum antibiotics. Mimics of the enzyme-bound intermediate of MbtI, isochorismate, prove to be significantly more potent inhibitors than the substrate, chorismate mimics <ref name= "manos-turvey"/>. Specifically, <scene name='69/694235/3rv6_with_vae1/1'>2-hydroxybenzoate-based inhibitors</scene> that contain extended hydrophobic enol ether side chains at C3 in place of the enol-pyruvate side chain found in chorismate and isochorismate.

Navigation menu